3-Methoxy-1-methyl-benzimidazolium iodid | 6595-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-Methoxy-1-methyl-benzimidazolium iodid
• 英文别名: 1-methoxy-3-methylbenzimidazol-3-ium;iodide
• CAS: 6595-47-7
• 化学式: C₉H₁₁N₂O*I
• 分子量: 290.104
• InChiKey: KCDJQVCUGATWAS-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.47
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  18
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-Methoxy-1-methyl-benzimidazolium iodid 以93%的产率得到
  参考文献：
  名称：

  POZHARSKIJ A. F.; KUZMENKO V. V.; KASHPAROV I. S.; SOKOLOV V. I.; MEDVEDE+, XIMIYA GETEROTSIKL. SOEDIN. , 1976, HO 3, 356-364

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-5-硝基-1H-1,3-苯并咪唑 、 2-溴苯乙酮 以60%的产率得到
  参考文献：
  名称：

  KAKEHI, AKIKAZU;ITO, SUKETAKA;SAKURAI, TOSIO;URUSHIDO, KUNIO;ISAWA, HIDET+, CHEM. AND PHARM. BULL., 38,(1990) N0, C. 2667-2675

  摘要：

  DOI：

文献信息

• Method for synthesizing 2-substituted imidazoles
  申请人：Sepracor Inc.

  公开号：US05817823A1

  公开（公告）日：1998-10-06

  The present invention is a method of preparing 2-substituted imidazoles from readily available imidazoles having a leaving group in the 2-position, by alkylating the imidazole under mild conditions to afford a 3-N-alkylated imidazolium salt; and coupling the imidazolium salt with a nucleophile also under mild conditions to afford a 2-substituted 3-N-alkylated imidazolium salt. The reaction product can optionally be isolated and purified. The 2-substituted 3-N-alkylated imidazolium salt is hydrolyzed to afford a 2-substituted imidazole. Alternatively, the imidazole is coupled with a nucleophile in the presence of fluoride ion to provide a 2-substituted imidazole.

  本发明提供了一种从具有2位离去基团的易得到的咪唑中制备2-取代咪唑的方法，通过在温和条件下烷基化咪唑以得到3-N-烷基化咪唑盐，然后在温和条件下将咪唑盐与亲核试剂偶联以得到2-取代的3-N-烷基化咪唑盐。反应产物可以选择性地分离和纯化。2-取代的3-N-烷基化咪唑盐水解后可得到2-取代咪唑。或者，在氟离子存在下，咪唑与亲核试剂偶联以提供2-取代咪唑。
• Cephalosporin derivatives
  申请人：ICI PHARMA

  公开号：EP0127992A2

  公开（公告）日：1984-12-12

  A cephalosporin derivative of the formula I: in which X is S, 0, CH2 or SO. R1 is (optionally- substituted)imidazol-2-yl or one of the C-7 acyl groups known in the cephalosporin art, R2 is hydrogen or methoxy, R3 is carboxy or a biodegradiable ester thereof and -R4 is of the formula XII, XIII or XIV: R35 in which R32-R40 inclusive are as defined in the specification; and the salts thereof. Pharmaceutical compositions methods of manufacture and intermediates are also described.

  式 I 的头孢菌素衍生物： 其中 X 是 S、0、CH2 或 SO。R1 是（任选取代的）咪唑-2-基或头孢菌素领域已知的 C-7 乙酰基之一，R2 是氢或甲氧基，R3 是羧基或其生物降解酯，-R4 是式 XII、XIII 或 XIV： R35 其中 R32-R40 包括在内如说明书中所定义；及其盐类。还描述了药物组合物的制造方法和中间体。
• Synthesis and structure-activity relationship of new cephalosporins with amino heterocycles at C-7. Dependence of the antibacterial spectrum and .beta.-lactamase stability on the pKa of the C-7 heterocycle
  作者：F. Jung、C. Delvare、D. Boucherot、A. Hamon、N. Ackerley、M. J. Betts

  DOI：10.1021/jm00107a035

  日期：1991.3

  Cephalosporins with new aminobenzimidazole and aminoimidazoline heterocycles at C-7 have been synthesized starting with versatile C-7 isocyanide dihalide synthons. The aminobenzimidazoles have a broad spectrum of antibacterial activity, including Gram-positive and Gram-negative organisms, but possess limited beta-lactamase stability. In contrast, the aminoimidazolines have a narrow spectrum of antibacterial activity, limited to Gram-negative strains only, but possess outstanding beta-lactamase stability. Structure-activity relationships are discussed in terms of their dependence on the pK(a) of the C-7 amino heterocycle, basic C-7 residues giving cephalosporins with exceptional beta-lactamase stability.
• JUNG, F.;DELVARE, C.;BOUCHEROT, D.;HAMON, A.;ACKERLEY, N.;BETTS, M. J., J. MED. CHEM., 34,(1991) N, C. 1110-1116
  作者：JUNG, F.、DELVARE, C.、BOUCHEROT, D.、HAMON, A.、ACKERLEY, N.、BETTS, M. J.

  DOI：——

  日期：——
• Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor
  申请人：ICI PHARMA

  公开号：EP0031708B1

  公开（公告）日：1984-06-13